<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656691</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0081_</org_study_id>
    <nct_id>NCT04656691</nct_id>
  </id_info>
  <brief_title>At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19</brief_title>
  <acronym>UNITED</acronym>
  <official_title>At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Griffin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Optum, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UnitedHealth Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, pragmatic, single-dose study using matched controls in participants&#xD;
      with mild to moderate COVID-19. Participants will track for developing symptoms while at home&#xD;
      and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time&#xD;
      at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants&#xD;
      will then track for 28 days to assess for any additional medical care needed or if&#xD;
      hospitalization was required.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - determining hospitalization rates</measure>
    <time_frame>28 days after infusion date</time_frame>
    <description>Determine the incidence of COVID-19 related hospitalization at day 28 among treated-participants relative to external controls.&#xD;
Long-term: hospitalization rate via medical records/claims data Short-term: participants self-report during active study participation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - documenting adverse events after infusion</measure>
    <time_frame>28 days after infusion date</time_frame>
    <description>Describe the incidence of infusion reactions recorded by the Optum Infusion nurse on the Case Report Form (CRF) during receipt of infusion and during the defined infusion follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Participants with COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bamlanivimab</intervention_name>
    <description>Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.</description>
    <arm_group_label>Participants with COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  UnitedHealthcare member&#xD;
&#xD;
          -  confirmed COVID-19 positive&#xD;
&#xD;
          -  located in an area where Bamlanivimab (LY3819253) is available for infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current (from first symptom report) hospitalization for COVID-19&#xD;
&#xD;
          -  prior administration of Bamlanivimab or other COVID-19 therapies&#xD;
&#xD;
          -  previous COVID-19 diagnosis&#xD;
&#xD;
          -  prior receipt of a COVID-19 vaccine&#xD;
&#xD;
          -  not authorized for patient use per the EUA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Griffin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProHealth New York - UnitedHealth Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QueryLab</name>
      <address>
        <city>Minnetonka</city>
        <state>Minnesota</state>
        <zip>55343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2</url>
    <description>Eli Lilly SARS-COV-2 Update</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UnitedHealth Group</investigator_affiliation>
    <investigator_full_name>Daniel Griffin</investigator_full_name>
    <investigator_title>Daniel Griffin, MD PhD CTropMed CTH</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>bamlanivimab</keyword>
  <keyword>UnitedHealth</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share participant level data with other projects or researchers.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

